Amneal Pharmaceuticals, Inc. Class A Stock News

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report First Quarter 2025 Results on May 2, 2025.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® Extended-Release Capsules in Parkinson's Disease.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced the U.S. launch of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration. This new ready-to-use oncology product reduces the comp...

Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA.